Ludwig Boltzmann Institute of Urology and Andrology, Municipal Hospital Hietzing, Wolkersbergenstrasse 1, 1130, Vienna, Austria.

This email address is being protected from spam bots, you need Javascript enabled to view it

The objective of the study was to determine whether intravesical pentosanpolysulfate (PPS) reduces symptoms associated with bladder pain syndrome/interstitial cystitis (BPS/IC). In a prospective, uncontrolled, open-label study, 29 female patients with BPS/IC received 300 mg PPS intravesically twice a week for 10 weeks and thereafter a voluntary maintenance therapy once a month. Treatment response was assessed by Visual Analog Scale (VAS) for quality of life and O'Leary-Sant Symptom and Problem Index (OSPI). Patients were tested before treatment, after 5 weeks of treatment, and 1 week, 3, 6, and 12 months after termination of the initial treatment. Twenty-five patients underwent the 10-week treatment and the 3-month follow-up. Mean reduction of VAS/OSPI was from 8.8/26.4 before to 4/15.3 after treatment, 3.8/15.2 after 3 months, 3.8/14 after 6 months, and 3.4/12.1 after 12 months. In 21 patients, renewed instillation or maintenance therapy was necessary. Intravesical treatment with PPS reduces both the VAS and the OSPI in patients with BPS/IC.

Written by
Daha LK, Lazar D, Simak R, Pflüger H.

Reference
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jan 29. Epub ahead of print.
doi:10.1007/s00192-008-0560-8

PubMed Abstract
PMID:18227956

UroToday.com Painful Bladder Syndrome Section

Please log-in or register in order to submit comments.

Powered by AkoComment!